Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Conditions

• Enlarged Heart
• Heart Attack

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• SGLT-2 inhibitors — DRUG
  SGLT2 inhibitor once daily for six months
• Placebo — DRUG
  Placebo once daily for six months

Study Details

The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.

Key Dates

Start date

Aug 3, 2022

Status verified

Oct 2024

Primary completion

Dec 31, 2028

Completion

Dec 31, 2028

Study Design

Enrollment

81 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Treatment Group
  Treatment group will receive SGLT2 inhibitor in addition to standard heart attack medications for the duration of hospitalization and 6-month duration of the study.
• Placebo Comparator: Placebo Group
  Placebo Group will receive placebo in addition to standard heart attack medications for the duration of hospitalization and 6-month duration of the study.

Primary Outcome Measure

Change in LVESVI [ Time Frame: 6 Months ]

Central Contacts

• Sarah Schwager, RN
  612-863-3833
  [email protected]

Locations (1)

Find similar trials in Minneapolis, MN

Related Studies

• Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
  Recruiting · AliveCor · Rochester, Minnesota
• Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
  Recruiting · University of Tennessee · Knoxville, Tennessee